Bibliography
- Cohen S, Shafferman A (Eds.), Plenum Press, New York (1996):183–189.
- BLAMEY RW: The introduction of the LHRH agonist, goserelin (7oladex') into clinical practice for endocrine-related cancer. JOURNAL (1997) 4:229–232.
- APHTON CORPORATION, INC.: Corporate Statements. http://www.aphton.com
- GLOVER JF, EN WRIGHT WJ, RUSHTON A: A GnRH analogue based immunotherapeutic for the palliative therapy of prostate cancer: pharmacological studies in the rat. British Prostate Group Meeting. York, UK (March 1996) :31. Abstract.
- PROTEUS INTERNATIONAL PLC: Annual Report and Accounts (1997). http://www.proteus.co.uk.
- New antiplatelet drugs. Drugs & Market Development (1997) 8(3):56–57.
- HERSEY P: Melanoma vaccines: prospects for the treatment of melanoma. Exp. Opin. Invest. Drugs (1997) 6(3):267–277.
- SPITLER LE, HARRIS DT, MASTRANGELO MJ, et al.: Clinical trials of cancer vaccines. Proceedings of the 3rd International Conference on Engineered Vaccines for Cancer and AIDS. Cambridge Symposia (1996).
- APHTON CORPORATION, INC.: Corporate Statements. http://www.aphton.com
- PROTEUS INTERNATIONAL PLC: Press Release (5 March 1998). http://www.proteus.co.uk.
- NEEFJES JJ, MOMBURG F: Cell biology of antigen presentation. Curr. Opin. Immunol. (1993) 5:27–34.
- ENGELHARD VH: How cells process antigens. Sci. Am. (August 1994):44–51.
- GREGORIADIS G: Immunological adjuvants: a role for liposomes. Immunology Today (1990) 11(3):89–97.
- BREWER JM, ALEXANDER J: Studies on the adjuvant activity of non-ionic surfactant vesicles: adjuvant-driven IgG2a production independent of MHC control. Vaccine (1994) 12(7):613–619.
- GUPTA RK, RELYVELD EH, LINDBLAD EB, et al.: Adjuvants - a balance between toxicity and adjuvanticity. Vaccine (1993) 11 (3) :293–305.
- BOON T: Teaching the immune system to fight cancer. Sci. Am. (March 1993):32–39.
- DONNELLY JJ, ULMER JB, LIU MA: Immunisation with polynucleotides: a novel approach to vaccination. The Immunologist (1994) 2(1) :20–26.
- POWDERJECT PHARMACEUTICALS PLC: Powderject & GlaxoWellcome sign DNA vaccine agreement. Press Release (5 March 1998).